You are here

Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

Last updated on July 10, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Vancouver, British Columbia, V5Z 4E6 Canada
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Head and Neck Neoplasms
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Recurrent or metastatic Squamous Cell Cancer of the Head and Neck;

- Measurable disease;

- Eastern Cooperative Oncology Group (ECOG) 0-1 in Stage 1 = first 23 patients;

- Eastern Cooperative Oncology Group (ECOG) 0-2 in Stage 2 = 33 patients;

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- prior therapy for recurrence;

- platelets

- prior Epidermal Growth Factor Receptor (EGFR) therapy;

- interstitial lung disease;

- primary of nasopharynx

NCT00768664
Pfizer
Completed
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now